EGFR and non-small cell lung carcinoma: The current standard-of-care in patients with advanced stage NSCLC harboring a sensitizing EGFR mutation, excluding exon 20 insertion mutations, is first-line systemic treatment with a first-, second-, or third-generation EGFR tyrosine kinase inhibitor (TKI) with or without monoclonal antibodies (e.g., bevacizumab and ramucirumab), dependent on the specific EGFR mutation(s)3.